Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Acquired by Royce & Associates LP

Royce & Associates LP increased its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 35.4% during the fourth quarter, Holdings Channel reports. The fund owned 1,965,114 shares of the medical instruments supplier’s stock after purchasing an additional 513,664 shares during the quarter. Royce & Associates LP’s holdings in Harvard Bioscience were worth $4,146,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in Harvard Bioscience by 63.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock valued at $79,000 after buying an additional 11,397 shares during the period. Barclays PLC increased its stake in Harvard Bioscience by 304.4% during the 3rd quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 44,150 shares during the period. State Street Corp increased its stake in Harvard Bioscience by 1.1% during the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after buying an additional 7,763 shares during the period. Geode Capital Management LLC increased its stake in Harvard Bioscience by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after buying an additional 19,972 shares during the period. Finally, Avior Wealth Management LLC increased its stake in Harvard Bioscience by 1,118.1% during the 3rd quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 13,373 shares during the period. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Stock Up 2.2 %

Harvard Bioscience stock opened at $0.69 on Thursday. The stock has a market cap of $30.03 million, a price-to-earnings ratio of -2.09 and a beta of 1.46. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. The company’s 50-day moving average price is $1.33 and its two-hundred day moving average price is $2.02. Harvard Bioscience, Inc. has a 52 week low of $0.60 and a 52 week high of $4.70.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.